Interpace Diagnostics Group (NASDAQ:IDXG) and Delcath Systems (OTCMKTS:DCTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.
This table compares Interpace Diagnostics Group and Delcath Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-55.67%||-33.16%||-24.09%|
12.3% of Interpace Diagnostics Group shares are owned by institutional investors. 2.8% of Interpace Diagnostics Group shares are owned by company insiders. Comparatively, 0.0% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Interpace Diagnostics Group and Delcath Systems’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Interpace Diagnostics Group||$21.90 million||1.25||-$12.19 million||($0.43)||-1.67|
|Delcath Systems||$2.71 million||0.46||-$45.11 million||N/A||N/A|
Interpace Diagnostics Group has higher revenue and earnings than Delcath Systems.
This is a breakdown of recent recommendations and price targets for Interpace Diagnostics Group and Delcath Systems, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||4||0||3.00|
Interpace Diagnostics Group presently has a consensus target price of $3.31, indicating a potential upside of 362.32%. Given Interpace Diagnostics Group’s higher possible upside, analysts plainly believe Interpace Diagnostics Group is more favorable than Delcath Systems.
Risk & Volatility
Interpace Diagnostics Group has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
Interpace Diagnostics Group beats Delcath Systems on 10 of the 11 factors compared between the two stocks.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Delcath Systems Company Profile
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.